Immune Registry Study Evaluating BK Virus Infection and Immune Responses in Adults Receiving Deceased Donor Kidney Transplants

What this Trial Is About

Kidney transplantation is a key treatment for advanced kidney disease, but success depends on balancing the risk of rejection and infections like BK virus. BK virus infection can cause significant complications after transplant, including kidney injury, rejection, and graft loss. The exact causes and treatment options for BK virus-related kidney disease are not fully clear, and it is debated whether the infection comes from the donor or is reactivated in the recipient. This research evaluates the role of adaptive immunity, focusing on cellular and humoral responses, in adults receiving deceased donor kidney transplants. The study includes a main group of transplant recipients enrolled at the time of transplant and a sub-study group of those newly diagnosed with BK viremia or difficult-to-treat BK virus infection. Researchers will collect blood and urine samples monthly for six months and clinical data to understand immune responses and monitor treatment approaches such as immunosuppression changes and intravenous immunoglobulins. Participants will be involved in providing blood and urine samples and sharing clinical information over a 24-month period to assess immune responses to BK virus under immunosuppression therapy. The study will track BK viremia frequency and immune response effects, using laboratory tests and clinical monitoring. This observational study aims to improve understanding of BK virus infection management in kidney transplant recipients by following participants for up to two years.

Immune Registry for BK in Kidney Transplant Recipients